Navigation Links
Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
Date:7/9/2008

Orexigen is the only company with two late-stage product candidates to

address a broad spectrum of obesity patients

SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) announced today that it has begun randomizing patients in ZB-202, a second Phase IIb clinical trial for Empatic(TM), one of the Company's two late-stage obesity product candidates. The trial is designed to build on highly encouraging safety and efficacy results from a previous Phase IIb trial of Empatic, which demonstrated robust weight loss at 48 weeks ranging from approximately 11 percent to 15 percent in obese patients completing the trial and a discontinuation rate due to adverse events that was not significantly different than placebo.

"Initiation of ZB-202 is an important milestone for our Empatic program and the final anticipated step before moving into Phase III development," said Gary Tollefson, M.D., Ph.D., Orexigen President and CEO. "Empatic continues to be an important component of the Company's obesity program. Along with Contrave(R), now in Phase III clinical trials, these product candidates both have the potential to target a large, distinct and complementary segment within the obesity market."

Orexigen is the only company currently developing two late-stage product candidates to address the full spectrum of obesity ranging from mild-to-moderate and moderate-to-severe obesity. Obesity has become a national epidemic, with more than 70 million Americans classified as obese and 300,000 deaths a year attributable to obesity, according to the Centers for Disease Control (CDC). Obesity is associated with a number of significant medical conditions, including diabetes, hypertension, high cho
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
2. Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
3. Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients
4. Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer
5. iCAD Initiates Clinical Study of Its Virtual Colonoscopy CAD in Partnership with ACR Image Metrix
6. Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
7. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
8. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
9. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
10. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
11. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...swire/ -- Celling Technologies, a subsidiary of Sp...nesis, Inc. to research potential applications for...ith acquired the global rights in spine for Tissue...echnology in November of 2007. Replacing the prio... Celling Technologies to further research adipose ...
(Date:11/9/2009)...RNewswire/ -- Women,s sexual health company, TivaM...eve as it prepares for a 2010 launch of its Viveve...Viveve is a name that we believe captures the esse..." said Kerry Pope, Viveve,s president and chief ex...lping women restore their sense of fulfillment and...
(Date:11/9/2009)...ewswire/ -- Access MediQuip, LLC, the nation,s fir...medical device management solutions to the healthc...g its corporate headquarters to Lake Mary, Florida...d growth, includes a major expansion of the Primer...anuary 2010 and relocation and expansion of the Ho...
Breaking Medicine Technology:Celling Technologies Signs Exclusive Agreement to Research and Develop Adipose Tissue Stem Cell Technology in Regenerative Medicine Institutes 2Celling Technologies Signs Exclusive Agreement to Research and Develop Adipose Tissue Stem Cell Technology in Regenerative Medicine Institutes 3Women's Sexual Health Company Changes Name in Preparation for Market Entry 2Access MediQuip Moves Company Headquarters to Lake Mary, Florida 2Perfect Fitness Ranks No 1 of Consumer Product Companies on 2009 Inc 500 List Ranks No 4 Overall 54327 1Perfect Fitness Ranks No 1 of Consumer Product Companies on 2009 Inc 500 List Ranks No 4 Overall 54327 2Verizon Wireless Offers Healthy Applications to Turn a Mobile Phone Into a Personal Trainer 54323 1Verizon Wireless Offers Healthy Applications to Turn a Mobile Phone Into a Personal Trainer 54323 2BioNeutrals Ygiene 28TM 29 Achieves Worlds Fastest Kill Time With a 100 25 Total Spore Eradication Verified In Independent Sporicidal Sterilant Test 54319 1BioNeutrals Ygiene 28TM 29 Achieves Worlds Fastest Kill Time With a 100 25 Total Spore Eradication Verified In Independent Sporicidal Sterilant Test 54319 2BioNeutrals Ygiene 28TM 29 Achieves Worlds Fastest Kill Time With a 100 25 Total Spore Eradication Verified In Independent Sporicidal Sterilant Test 54319 3BioNeutrals Ygiene 28TM 29 Achieves Worlds Fastest Kill Time With a 100 25 Total Spore Eradication Verified In Independent Sporicidal Sterilant Test 54319 4
...itive Phase II Results of Roche and Ipsen,s First ...can Diabetes Association Meeting -, NUTLEY, N.J.,... diabetes drug taspoglutide (R1583) has been shown...ntrol and weight loss after only,eight weeks of tr...e that,supports entry into Phase III. Taspoglutide...
...AIN VIEW, Calif., June 9 Alexza,Pharmaceuticals, ...results,from its Phase 2a proof-of-concept clinica...tients with panic disorder. The study did not meet...of AZ-002 on the incidence of a,doxapram-induced p...on of a,doxapram-induced panic attack, both as com...
Other Medicine Technology:Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials 2Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials 3Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials 4Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials 5Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials 6Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 2Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 3Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 4
(Date:11/9/2009)...ion backs President Obama,s promise to not expand ... ,, Bishops still concerned for poor, elderly ...-- Cardinal Francis George of Chicago, president o..., lauded the November 7 decision of the U.S. House...eform money from paying for elective abortions. ,...
(Date:11/9/2009)...ports success with drugs that inhibit estrogen, ,...o drugs used to treat breast cancer and osteoporos...o a new study. , The drugs also cleared precanc...ted the onset of cancer in mice with precancerous ...nd the breast cancer/osteoporosis drug raloxifene ...
(Date:11/9/2009)...n and women almost equally, study finds, , ...y used clot-dissolving drug Plavix (clopidogrel) w...s of major clinical trials has found. , "After ...ing both men and women with this very important dr...ovascular thrombosis at New York University Langon...
(Date:11/9/2009)... Networking is everybody,s buzz word toda...StaffingClub.com enables Recruiters and Staffers c...nect, share, communicate and close positions. The ...heir profiles and network with recruiters. , ...rrent Job Market forces everyone to network more t...
(Date:11/9/2009)...ve letter formation could boost self-esteem, resea... News) -- Autistic children are more likely to hav...letters, than those without autism, researchers sa... to 13. Half of the study participants had autism ...within the normal range for perceptual reasoning o...
Breaking Medicine News(10 mins):Health News:Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly 2Health News:Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly 3Health News:Breast Cancer Drugs May Fight Cervical Cancer, Too 2Health News:No Gender Gap Found for Clot-Busting Drug 2Health News:No Gender Gap Found for Clot-Busting Drug 3Health News:Launching StaffingClub.com, a New Online Networking Platform for Recruiting and Staffing Professionals 2Health News:Handwriting Skills May Lag in Kids With Autism 2
...g 15 pounds or more over several years puts one at...are obese but maintain a stable weight . Resea... and 30 over 15 years. Most participants gained 15...s. But only 4 percent of those who didn't gain the...
...in optimum cardiovascular health can not only affe...rs .// Researchers say they have found a link ...or cognitive impairment in the elderly. The condit...ls of High Density Lipoprotein . During a span ...
...l tissue, which is normally found only in the lini... attaches itself to ligaments and organs in the ab...mptoms include pain, bleeding, inflammation, adhes...rs studied 133 women with endometriosis and a cont...
...ay be a strong link between Skin Allergies and can... may actually be more prone //to blood related can...ers reported this finding in a study in the recent...kemia and those of us who have as children suffer...
...ple researchers say dads who have children at an o...veloping schizophrenia later in life. Research...mitted to the hospital in Sweden between 1989 and ... conception and their children's risk of becoming ...
...s for viral RNA among organ and tissue donors who ...se // transmission among transplant recipients, sa...r the presence of blood antibodies to diseases suc...mune response. For the study 2,236 organ donors...
Other Medicine News:
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
Medicine Products: